- 292 Downloads
Mometasone, a synthetic 16α-methyl analogue of beclomethasone, is classified as a ‘potent’ glucocorticoid for dermatological use. It is available as 0.1% cream, ointment and lotion formulations for the treatment of patients with inflammatory glucocorticoid-responsive dermatoses.
In patients with atopic dermatitis, the effects of mometasone 0.1% applied once daily over 2 to 3 weeks were similar to those of other glucocorticoids of similar potency, such as betamethasone dipropionate 0.05% twice daily and methylprednisolone aceponate 0.1% once daily. Mometasone 0.1% was significantly superior to twice-daily application of less potent glucocorticoids such as clobetasone 0.05%, hydrocortisone 1.0%, hydrocortisone butyrate and hydrocortisone valerate 0.2%. In patients with seborrhoeic dermatitis, mometasone 0.1% was more effective than ketoconazole 2.0% and hydrocortisone 1.0% in trials lasting 4 or 6 weeks. In the management of scalp psoriasis and psoriasis vulgaris, mometasone 0.1% applied once daily for 2 to 8 weeks was generally more effective than other glucocorticoids of similar or weaker potency such as betamethasone valerate 0.1%, fluocinolone acetonide 0.025%, fluticasone propionate 0.005%, triamcinolone acetonide 0.1% and hydrocortisone 1.0% and as effective as diflucortolone valerate 0.1%. Alternate day application of mometasone 0.1% for 2 weeks was as effective as once-daily application in maintaining symptom control in a small number of patients with psoriasis vulgaris.
Although mometasone demonstrates greater anti-inflammatory activity and a longer duration of action than betamethasone, it has low potential to cause adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Moreover, its atrophogenic potential is low and no greater than that of other glucocorticoids in its class, such as betamethasone valerate. Transient, mild to moderate, local adverse effects such as burning, stinging, folliculitis, dryness, acneiform eruptions and signs of skin atrophy have been reported with mometasone. Mometasone has shown a low risk of primary sensitisation and cross-reactions in preliminary patch test studies.
Mometasone is a well tolerated topical glucocorticoid effective in the management of patients with atopic dermatitis, seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris. In addition to its low potential for causing primary sensitisation and cross-reactions with other topical glucocorticoids, mometasone offers the convenience of once-daily administration.
Mometasone has high lipophilicity and displays greater in vitro affinity for glucocorticoid receptors in rat epidermis than betamethasone dipropionate. In suppressing erythema induced by ultraviolet (UV)-B light, mometasone showed greater activity and a longer duration of action than betamethasone dipropionate and betamethasone valerate. However, it showed little potential to suppress the hypothalamic-pituitary-adrenal axis in patients and healthy volunteers.
An in vitro study on human fibroblasts and keratinocytes reported the anti-proliferative effects of mometasone to be negligible or small compared with those of betamethasone valerate. No clinical or histological signs of skin atrophy were observed in 6 volunteers after 12 months of once-daily application of mometasone 0.1% cream. Some clinical trials have found the atrophogenic potential of mometasone to be low and similar to that of hydrocortisone, prednicarbate, betamethasone valerate and methylprednisolone aceponate. However, in one trial, mometasone 0.1% ointment was associated with a significantly greater incidence and severity of skin atrophy and telangiectasia than methylprednisolone aceponate 0.1% ointment.
Little topically applied mometasone reaches the systemic circulation. In human volunteers, only 0.7% of mometasone 0.1% ointment was systemically absorbed after a contact time of 8 hours without occlusive dressing. After application of 10g 0.1% ointment under occlusion, the plasma concentration of mometasone peaked at about 130 ng/L in 12 hours and then declined rapidly.
Atopic dermatitis. In short term studies (≤6 weeks) once-daily mometasone 0.1% cream or ointment was significantly more effective in reducing total sign and symptom severity scores than twice-daily clobetasone 0.05% ointment, clobetasone 0.05% cream, hydrocortisone butyrate cream, hydrocortisone valerate 0.2% cream and hydrocortisone 1.0% cream and as effective as once-daily methylprednisolone aceponate 0.1% cream or twice-daily betamethasone dipropionate 0.05% ointment in the treatment of moderate to severe atopic dermatitis.
Seborrhoeic dermatitis. Once-daily application of mometasone 0.1% solution was more effective and showed a faster onset of action than ketoconazole 2.0% shampoo applied twice weekly over 4 weeks in the treatment of patients with moderate to severe seborrhoeic dermatitis. Significantly greater improvement was observed after 6 weeks with mometasone 0.1% cream applied once daily than with hydrocortisone 1.0% cream applied twice daily. Psoriasis. Mometasone 0.1% lotion or ointment applied once daily was significantly more effective than twice-daily betamethasone valerate 0.1% lotion or ointment over 2 to 8 weeks in 3 trials in patients with scalp psoriasis or psoriasis vulgaris. The once-daily application of mometasone 0.1% cream, lotion or ointment formulations produced significantly greater reductions in total psoriatic symptom scores than once-daily hydrocortisone 1% ointment, twice-daily fluticasone propionate 0.005% ointment, triamcinolone acetonide 0.1% lotion or ointment or 3-times-daily fluocinolone acetonide 0.025% cream or ointment. In patients with psoriasis vulgaris, mometasone applied once daily was as effective as twice-daily diflucortolone valerate 0.1% ointment and triamcinolone acetonide 0.1% cream. Results of a preliminary short term study suggest that application of mometasone 0.1% ointment on alternate days may be as effective as once-daily application in maintenance therapy in patients with psoriasis vulgaris.
Topical mometasone 0.1% cream was associated with local cutaneous adverse effects in 1.6 and 7.0% of 319 adult and 74 paediatric patients, respectively. The most commonly encountered adverse effects included stinging, burning, pruritus, folliculitis, dryness, acneiform/erythematous eruptions, tenderness and signs of skin atrophy. These adverse effects were transient and of mild or mild to moderate intensity.
Preliminary patch test studies have reported that the risk of primary sensitisation or cross-reaction with mometasone is low, even in patients known to be hypersensitive to glucocorticoids.
Dosage and Administration
Mometasone 0.1% cream, ointment or lotion is indicated for the symptomatic relief of inflammation and pruritus in patients with glucocorticoid-responsive dermatoses. It should be applied without occlusion to the affected areas once daily. Like other topical glucocorticoids, mometasone should not be used in patients with primary cutaneous viral, bacterial or fungal infections, rosacea, acne, perioral dermatitis, or perianal or genital pruritus. It may be used with caution in children aged ≥2 years.
Unable to display preview. Download preview PDF.
- 4.Popper TL, Gentles MJ, Kung TT, et al. Structure-activity relationships of aseries of novel topical corticosteroids. J Steroid Biochem Mol Biol 1987; 27(4–6): 837–43Google Scholar
- 6.Gustafsson JA, Carlstedt-Duke J, Stromstedt PE, et al. Structure, function and regulation of the glucocorticoid receptor. Prog Clin Biol Res 1990; 322: 889–95Google Scholar
- 24.Nissen JB, Kragballe K. Enkephalin levels in psoriatic skin after treatment with cacipotriol, mometasone furoate and heliobalneotherapy [abstract no. 349]. J Invest Dermatol 1997; 107: 462Google Scholar
- 25.Berti E, Richelda R, Bianchi B, et al. Evaluation of infiltrate cytokines receptors and adhesion molecules expression in psoriasis during topical treatment with mometasone furoate [abstract no. P-72]. In: American Academy of Dermatology: 1995 Annual Meeting Program supplement. New Orleans (LA), 1995Google Scholar
- 26.Bjerring P. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans-inhibition of UV-B-induced inflammation monitored by laser doppler blood flowmetry. Skin Pharmacol 1993; 6(3): 187–92PubMedCrossRefGoogle Scholar
- 29.Brannan MD, Herron JM, Reidenberg P, et al. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract]. 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology: 1996: 76Google Scholar
- 30.Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1%, on adrenocortical function in psoriasis patients. Today’S Ther Trends 1988; 5(4): 25–35Google Scholar
- 32.Higashi N, Katagiri K. Percutaneous absorption of 0.1% mometasone furoate ointment fate, excretion and adrenocortical suppression [in Japanese]. Skin Res 1990; 32(3): 395–402Google Scholar
- 34.Hoybye A, Moller SB, De Cunha Bang F, et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res 1991 Jul; 50: 67–72Google Scholar
- 36.Ishibashi Y, Harada S, Niimura M, et al. Long term topical application of 0.1% mometasone furoate ointment and cream. Studies on systemic effects, local adverse reactions and clinical effects [in Japanese] [English abstract]. Rinsho Iyaku 1990 Aug; 6: 1655–69Google Scholar
- 40.Robertson DB, Maibach HI. Topical glucocorticoids. In: Schleimer RP, Claman HN, Oronsky A, editors. Anti-inflammatory steroid action. San Diego: Academic Press, 1989: 494–524Google Scholar
- 41.Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatol Clin 1984; 2: 397–409Google Scholar
- 43.Hein R, Bosserhoff A, Wach F, et al. Effect of a newly synthesized glucocorticosteroid—mometasone furoate: on human keratinocytes and fibroblasts in vitro [abstract]. In: International Meeting Skin Therapy Update 94: 1994: 256Google Scholar
- 46.Brasch J. The atrophogenic potential of mometasone furoate in a clinical long-term study [in German] [English abstract]. Z Hautkr 1991; 66(9): 785–7Google Scholar
- 48.Hoffman K, Auer T, Stucker M, et al. Skin atrophy and vasoconstriction with mometasone furoate compared with methylprednisolone and hydrocortisone. Schering-Plough Corporation Limited, data on file, November, 1997Google Scholar
- 49.Schering Corporation. Product information. Kenilworth (NJ): Schering Corporation, 1995. (Data on file)Google Scholar
- 51.Lebwohl M, Lane AT, Berman B, et al. Efficacy and safety of 0.1% mometasone furoate cream versus 0.2% hydrocortisone valerate cream in pediatric patients with atopic dermatitis unresponsive to topical hydrocortisone treatment [abstract no. P-43]. Proceedings of the 55th Annual Meeting of the American Academy of Dermatology: 1997 Mar 21–26: San FranciscoGoogle Scholar
- 52.Bianchi B. Practical application of the SCORAD index in a clinical trial of children and adults with atopic dermatitis. Poster presentation in the 19th World Congress of Dermatology; 1997 Jun 15–20: SydneyGoogle Scholar
- 53.Giannetti A, Manzini BM, Bianchi B. Randomized, evaluation-blinded, multicenter study on onset of action, efficacy and safety of mometasone furoate 0.1% cream vs clobetasone butyrate 0.05% ointment in the treatment of atopic dermatitis [abstract no. P-229]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans (LA), 1995Google Scholar
- 54.Marchesi E, Rozzoni M, Pini P, et al. Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis. G Ital Dermatol Venereol 1994; 129(1–2): IX–XIIGoogle Scholar
- 59.Vanderploeg DE, Cornell RC, Binder R, et al. Clinical trial in scalp psorisis. Mometasone furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Ther 1989 Apr; 15: 145–52Google Scholar
- 62.Medansky RS, Brody NI, Kanof NB, et al. Clinical investigations of mometasone furoate—a novel nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6(2): 94–100Google Scholar
- 63.De Panfilis G, Braga D, Bianchi B. A randomised, multicentric, evaluator blinded study to compare mometasone furoate 0.1% ointment versus diflucortolone valerate 0.1% ointment in the treatment of psoriasis vulgaris [abstract no. P-111]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans, LA, 1995Google Scholar
- 64.De Villez RL, Sher.AM, Breneman DL, et al. Comparison of the efficacy and safety of mometasone furoate ointment 0.1% once daily and fluticasone propionate ointment 0.005% twice daily in the management of psoriasis. Schering-Plough Corporation Limited, Kenilworth (NJ), 1997. (Data on file)Google Scholar
- 65.Santoro G, Fiallo P, Tagliapietra G, et al. Mometasone furoato a giorni alterni nel trattamento della psoriasi. G Ital Dermatol Venereol 1996; 131: 407–12Google Scholar
- 67.Bianchi B. Mometasone furoate and methylprednisolone aceponate in patients with contact dermatitis. Poster presentation in the 19th World Congress of Dermatology, Sydney, Australia, Jun 15–20, 1997Google Scholar
- 68.Dominguez L, Hojyo T, Vega E, et al. Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses. Curr Ther Res 1990 Jul; 48: 128–39Google Scholar
- 69.Gip L, Lindberg L, Nordin P, et al. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Today’s Ther Trends 1990; 8(3): 21–34Google Scholar
- 73.Dooms-Goossens A, Lepoittevin J-R Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study. Eur J Dermatol 1996 Jul–Aug; 6: 339–40Google Scholar
- 80.Hsieh KH, Tsai YT. Increasing prevalence of childhood allergic disease in Taipei,Taiwan, and the outcome. In: Miyamoto T, Okuda M, editors. Progress in allergy and clinical immunology. Gottingen: Hogrefe & Huber, 1992: 223–5Google Scholar
- 81.Hogan PA. Atopic dermatitis. Patient Manage N Z 1997 Apr; 26: 35–43Google Scholar
- 83.Dutz JP, Ho VC. Immunosuppressive agents in skin disorders:a comparative review. Clin Ther 1996; 5(4): 268–93Google Scholar